PARADIGM BIOPHARMACEUTICALS
They focus on repurposing pentosan polysulphate sodium (PPS) for new orthopaedic and respiratory applications. They address conditions that start with and are sustained by inflammation. Lead clinical indications involve treating injury that results in bone marrow edema (BME) and the allergic inflammatory response in allergic rhinitis (AR), which is commonly known as ‘Hay Fever’.
PARADIGM BIOPHARMACEUTICALS
Industry:
Biotechnology Health Care Medical
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.paradigmbiopharma.com
Total Employee:
51+
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
TiENLAND
Australian Pharmaceutical Health Products
Current Employees Featured
Stock Details
Official Site Inspections
http://www.paradigmbiopharma.com Semrush global rank: 4.78 M Semrush visits lastest month: 1.92 K
- Host name: server-3-162-112-87.iad61.r.cloudfront.net
- IP address: 3.162.112.87
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Paradigm Biopharmaceuticals"
Executive Team - Paradigm Biopharmaceuticals
Dr. Skerrett, has more than 30 years’ experience in transfusion medicine, cellular therapy, and regenerative medicine. She was the CMO of Mesoblast, a stem cell development company, from 2011-19; Dir. Transfusion Medicine & Cellular …See details»
Paradigm Biopharmaceuticals Company Profile | Management and …
Www.paradigmbiopharma.com . Paradigm Biopharmaceuticals Profile and History. Paradigm Biopharmaceuticals (ASX: PAR) is a global biopharmaceutical company driven to improve …See details»
Paradigm Biopharma - Org Chart, Teams, Culture & Jobs - The Org
Paradigm Biopharma (PAR) listed on the ASX in August 2015. Paradigm Biopharma's focus is on repurposing pentosan polysulphate sodium (PPS) for the treatment of diseases sustained by …See details»
Paradigm Biopharmaceuticals CEO and Key Executive Team
Paradigm Biopharmaceuticals's Executive Chairman and CEO is Paul Rennie. Other executives include Ravi Krishnan, Chief Scientific Officer; Melanie Duiker, Clinical Operations Director …See details»
Org Chart Paradigm Biopharma - The Official Board
For each of our 1,262,630 listed executives, discover their exact roles and their biographies.See details»
Paradigm Biopharmaceuticals - Crunchbase Company Profile
Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver pharmaceutical therapies to improve patients’ health and quality of lifeSee details»
PAR Company Description - Stock Analysis
Dec 4, 2024 Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable …See details»
Paradigm Biopharmaceuticals - VentureRadar
"Paradigm Pharmaceuticals is a commercially focussed drug repurposing company. We take an existing approved drug, which has demonstrated safety in its approved indication/s and …See details»
About Paradigm - Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals (Paradigm, ASX:PAR) is a commercially-focused drug development company.See details»
Paradigm Biopharmaceuticals - BIO International Convention | BIO
Jun 6, 2023 Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, …See details»
Board - Paradigm Biopharmaceuticals
Dr. Skerrett, has more than 30 years’ experience in transfusion medicine, cellular therapy, and regenerative medicine. She was the CMO of Mesoblast, a stem cell development company …See details»
In-depth: Paradigm Biopharmaceuticals Ltd - Baker Young
Mar 17, 2021 All the makings of a first-class blockbuster drug. Paradigm Biopharmaceuticals Limited (ASX:PAR) begins 2021 on the cusp of several pivotal Phase 3 clinical trials, with …See details»
Paradigm Biopharmaceuticals - businessnews.com.au
Dec 2, 2024 Paradigm Biopharmaceuticals Limited (PAR) is an Australian biopharmaceutical company focused on repurposing the drug 'pentosan polysulphate sodium' (PPS) for the …See details»
Paradigm Biopharmaceuticals - Overview, News & Similar
Nov 22, 2023 Who is Paradigm Biopharmaceuticals. Paradigm Biopharmaceuticals (ASX: PAR) is a global biopharmaceutical company driven to improve patients' lives through repurposing …See details»
Paradigm Biopharmaceuticals Ltd, PAR:ASX profile - FT.com
Nov 22, 2024 Paradigm Biopharmaceuticals Ltd (PAR:ASX) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.See details»
Paradigm Biopharmaceuticals Limited - AnnualReports.com
Www.paradigmbiopharma.com . PARADIGM BIOPHARMACEUTICALS LIMITED 3 CHAIRMAN’S REPORT Dear Shareholders, I am pleased to present the 2018 Annual Report for Paradigm …See details»
Paradigm Biopharmaceuticals - Craft
Oct 4, 2024 Paradigm Biopharmaceuticals $66 k in annual revenue in FY 2024. See insights on Paradigm Biopharmaceuticals including office locations, competitors, revenue, financials, …See details»
Product Development - Paradigm Biopharmaceuticals
Intellectual property is an important part of Paradigm’s strategic development and ownership of its drug development programs. Paradigm’s PPS has a multi-faceted raft of protection …See details»
Development Experts - Paradigm Biopharmaceuticals
New drugs approved by the FDA and other regulatory bodies have a long path to approval. An already-approved active pharmaceutical ingredient (API) that used in a novel way to treat …See details»